Back to Search
Start Over
Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.
- Source :
- British Journal of Cancer; 12/18/2006, Vol. 95 Issue 12, p1648-1652, 5p, 4 Charts, 1 Graph
- Publication Year :
- 2006
-
Abstract
- Irinotecan and cisplatin demonstrated promising outcomes in extensive-stage small-cell lung cancer. According to the dosage and schedule of irinotecan, efficacy and toxicity profiles showed subtle differences. This study was designed to evaluate efficacy and toxicity of 3-week schedule of irinotecan/cisplatin in patients with previously untreated extensive-stage small-cell lung cancer. The primary objective was to evaluate response rate and secondary objectives were overall survival and progression-free survival. Patients with previously untreated extensive-stage small-cell lung cancer were enrolled. Irinotecan 65 mg m-2 was administered on days 1 and 8 and cisplatin 60 mg m-2 on day 1. Treatment was repeated every 3 weeks. Seven out of 54 patients (13.0%) had complete response, and partial response was observed in 33 (61.1%). The overall response rate was 74.1% (95% CI; 62.0-82.2%). Stable disease was observed in eight (14.8%) and no progressive disease was observed. After a median follow-up duration of 28.7 months, the median overall survival and progressive-free survival were 13.6 and 6.5 months, respectively. Major grade 3/4 toxicities were neutropenia (50.0%), anorexia (42.6%), diarrhoea (29.6%), fatigue (29.6%) and vomiting (13.0%). There was one treatment-related death owing to pneumonia. Three-week schedule of irinotecan/cisplatin showed effective antitumour activity and moderate toxicities in patients with previously untreated extensive-stage small-cell lung cancer. [ABSTRACT FROM AUTHOR]
- Subjects :
- SMALL cell lung cancer
CANCER treatment
TOXICITY testing
CISPLATIN
RESPONSE rates
ANTINEOPLASTIC agents
BONE tumors
CAMPTOTHECIN
CLINICAL trials
COMPARATIVE studies
DRUG administration
LUNG tumors
RESEARCH methodology
MEDICAL cooperation
METASTASIS
RESEARCH
SURVIVAL
TUMOR classification
EVALUATION research
TREATMENT effectiveness
SALVAGE therapy
SMALL cell carcinoma
Subjects
Details
- Language :
- English
- ISSN :
- 00070920
- Volume :
- 95
- Issue :
- 12
- Database :
- Complementary Index
- Journal :
- British Journal of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 23421527
- Full Text :
- https://doi.org/10.1038/sj.bjc.6603500